Skip to Content

'
Roy F Chemaly, M.D., M.P.H., F.A.C.P., F.I.D.S.A.

Present Title & Affiliation

Primary Appointment

Professor, Department of Infectious Diseases, Infection Control and Employee Health, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Adjunct Professor, The University of Texas School of Public Health, Houston, TX
Adjunct Professor, Baylor College of Medicine, Houston, TX

Office Address

The University of Texas MD Anderson Cancer Center
1515 Holcombe Boulevard
Unit 1460
Unit Number: 1460
Houston, TX 77030-4095
Room Number: FCT12.6078
Phone: (713) 792-6830
Fax: (713) 792-5381

Education & Training

Degree-Granting Education

1992 Saint Joseph University, Faculty of Medicine, Beirut, Lebanon, MD, Doctor of Medicine

Postgraduate Training

7/2001-6/2002 Fellowship, Clinical Microbiology, The Cleveland Clinic Foundation, Cleveland, OH
10/2000-6/2002 Masters in Public Health, Northeastern Ohio Universities, Rootstown, OH
7/1998-6/2000 Fellowship, Infectious Diseases, The Cleveland Clinic Foundation, Cleveland, OH
1/1997-1/1998 Chief Medical Resident, Staten Island University Hospital, Staten Island, NY
8/1994-6/1997 PGYI, PGYII, PGYIII, Staten Island University Hospital, Staten Island, NY
7/1993-6/1994 Internship, Internal Medicine, American University Hospital, Beirut, Lebanon

Board Certifications

2001 American Board of Pathology Medical Microbiology Subspecialty
2000 American Board of Internal Medicine Infectious Diseases Subspecialty
1997 American Board of Internal Medicine

Experience/Service

Academic Appointments

Associate Professor, Department of Infectious Diseases, Infection Control and Employee Health, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 8/2008-9/2013

Honors and Awards

2012 Recognition for Act++ Project, MDACC Office of Performance Improvement
2011-2012 Best Doctor, US News Health
2011-2012 Top Doctor, Castle Connolly Medical Ltd.
2010 2nd Place Winner for Outstanding Patient Safety and Quality Improvement Project entitled "VAP can be eradicated"., Clinical Safety and Effectiveness Conference, November 4-5, 2010, Austin, Texas.
2009 Certificate of completion, 2009 Junior Heart of Leadership Program, MD Anderson Cancer Center
2008 Awarded Best Clinical Poster Presentation (Mentor to Dr. Karen Vigil) Second Infections in Cancer Symposium, The University of Texas M. D. Anderson Cancer Center
2008 Medical Leadership Award for the Infections in Cancer Symposium, The University of Texas M. D. Anderson Cancer Center, Houston, Texas
2008 Patient Safety Champion Award (related to the investigation of the Serratia marescens Outbreak), The University of Texas M. D. Anderson Cancer Center, Houston, Texas
2007 America's Top Physician, Consumers Research Council of America
2007 Certificate of Appreciation (for providing excellent protocol review), The University of Texas M. D. Anderson Cancer Center
2007 Fellow, Infectious Disease Society of America
2007 Fellow, The American College of Physicians
2007 Second Prize Winner (Mentor for Dr. Harrys Torres) for outstanding poster at the Annual Meeting, Texas Infectious Diseases Society
2005 First Prize Winner for our work on Influenza Infections in Leukemia Patients and the Impact of Neuraminidase Inhibitors (Mentor to Harrys Torres, MD), The First Biannual National Meeting for Infection in Cancer Symposium, Houston, Texas
2005 Leadership Award, Alumni Association of North America, American University of Beirut
2000 Finalist Award, Infectious Diseases Society of Ohio

Selected Publications

Peer-Reviewed Original Research Articles

1. Mahajan SN, Ariza-Heredia EJ, Rolston KV, Graviss LS, Feig BW, Aloia TA, Chemaly RF. Perioperative Antimicrobial Prophylaxis for Intra-abdominal Surgery in Patients with Cancer: A Retrospective Study Comparing Ertapenem and Nonertapenem Antibiotics. Ann Surg Oncol. e-Pub 10/10/2013. PMID: 24114052.
2. Wilhelm K, Chemaly R, Saliba R, Gulbis A, Saunders I, Cool R, Ferguson J, Westmoreland M, Rondon G, Kebriaei P. The impact of pre-transplant valganciclovir on early cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation. J Oncol Pharm Pract. e-Pub 9/9/2013. PMID: 24022408.
3. Yilmaz M, Chemaly RF, Han XY, Thall PF, Fox PS, Tarrand JJ, De Lima MJ, Hosing CM, Popat UR, Shpall E, Champlin RE, Qazilbash MH. Adenoviral infections in adult allogeneic hematopoietic SCT recipients: a single center experience. Bone Marrow Transplant 48(9):1218-23, 9/2013. e-Pub 3/18/2013. PMID: 23503529.
4. Chemaly RF, Torres HA, Munsell MF, Shah DP, Rathod DB, Bodey GP, Hosing C, Saifan C, Raad II, Champlin RE. An adaptive randomized trial of an intermittent dosing schedule of aerosolized ribavirin in patients with cancer and respiratory syncytial virus infection. J Infect Dis 206(9):1367-71, 11/2012. PMCID: PMC3466999.
5. Chemaly RF, Vigil KJ, Saad M, Vilar-Compte D, Cornejo-Juarez P, Perez-Jimenez C, Mubarak S, Salhab M, Jiang Y, Granwehr B, Adachi JA, Raad II. A multicenter study of pandemic influenza a (H1N1) infection in patients with solid tumors in 3 countries: Early therapy improves outcomes. Cancer 118(18):4627-33, 9/2012. PMID: 22359314.
6. Shah DP, El Taoum KK, Shah JN, Vigil KJ, Adachi JA, Granwehr BP, Tarrand JJ, Raad II, Chemaly RF. Characteristics and Outcomes of Pandemic 2009/H1N1 versus Seasonal Influenza in Children with Cancer. Pediatr Infect Dis J 31(4):373-8, 4/2012. e-Pub 1/5/2012. PMID: 22228234.
7. Chemaly RF, Hanmod SS, Rathod DB, Ghantoji SS, Jiang Y, Doshi A, Vigil K, Adachi JA, Khoury AM, Tarrand J, Hosing C, Champlin R. The characteristics and outcomes of parainfluenza virus infections in 200 patients with leukemia or recipients of hematopoietic stem cell transplantation. Blood 119(12):2738-45; quiz 2969, 3/22/2012. e-Pub 1/12/2012. PMID: 22246027.
8. Anaya DA, Cormier JN, Xing Y, Koller P, Gaido L, Hadfield D, Chemaly RF, Feig BW. Development and Validation of a Novel Stratification Tool for Identifying Cancer Patients at Increased Risk of Surgical Site Infection. Ann Surg 255(1):134-9, 1/2012. e-Pub 12/2/2011. PMID: 22143206.
9. Marty FM, Ljungman P, Papanicolaou GA, Winston DJ, Chemaly RF, Strasfeld L, Young JA, Rodriguez T, Maertens J, Schmitt M, Einsele H, Ferrant A, Lipton JH, Villano SA, Chen H, Boeckh M, Maribavir 1263-300 Clinical Study Group. Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial. Lancet Infect Dis 11(4):284-92, 4/2011. e-Pub 3/21/2011. PMID: 21414843.
10. Stibich M, Stachowiak J, Tanner B, Berkheiser M, Moore L, Raad I, Chemaly RF. Evaluation of a pulsed-xenon ultraviolet room disinfection device for impact on hospital operations and microbial reduction. Infect Control Hosp Epidemiol 32(3):286-8, 3/2011. PMID: 21460515.
11. Safdar A, Rodriguez GH, Mihu CN, Mora-Ramos L, Mulanovich V, Chemaly RF, Champlin RE, Khouri I. Infections in Nonmyeloablative Hematopoietic Stem Cell Transplantation Patients with Lymphoid Malignancies: Spectrum of Infections, Predictors of Outcome, and Proposed Guidelines for Fungal Infection Prevention. Bone Marrow Transplant 45(2):339-47, 2/2010. PMID: 19561648.
12. Chemaly RF, Hachem RY, Husni RN, Bahna B, Abou Rjaili G, Waked A, Graviss L, Nebiyou Bekele B, Shah JN, Raad II. Characteristics and Outcomes of Methicillin-Resistant Staphylococcus aureus Surgical-Site Infections in Patients with Cancer: a Case-Control Study. Ann Surg Oncol 17(6):1499-506, 2010. PMID: 20127184.
13. Chaftari AM, Hachem R, Mulanovich V, Chemaly RF, Adachi J, Jacobson K, Jiang Y, Raad I. Efficacy and safety of daptomycin in the treatment of Gram-positive catheter-related bloodstream infections in cancer patients. Int J Antimicrob Agents 36(2):182-6, 2010. PMID: 20452752.
14. Adachi JA, Perego C, Graviss L, Dvorak T, Hachem R, Chemaly RF, Raad II. The role of interventional molecular epidemiology in controlling clonal clusters of multidrug resistant Pseudomonas aeruginosa in critically ill cancer patients. Am J Infect Control 37(6):442-6, 8/2009. PMID: 19118923.
15. Chemaly RF, Hanmod SS, Jiang Y, Rathod DB, Mulanovich V, Adachi JA, Rolston KV, Raad II, Hachem RY. Tigecycline use in cancer patients with serious infections: a report on 110 cases from a single institution. Medicine (Baltimore) 88(4):211-20, 7/2009. PMID: 19593226.
16. Vigil KJ, Mulanovich VE, Chemaly RF, Tarrand J, Raad II, Adachi JA. Severe parainfluenza virus type 2 supraglottitis in an immunocompetent adult host: an unusual cause of a paramyxoviridae viral infection. J Intern Med 265(3):397-400, 3/2009. PMID: 19019183.
17. Aisenberg G, Torres H, Tarrand J, Safdar A, Bodey G, Chemaly RF. Herpes Simplex Virus Lower Respiratory Tract Infection in Patients with Solid Tumors. Cancer 115(1):199-206, 1/2009. PMID: 19090003.
18. Hachem RY, Kontoyiannis DP, Chemaly RF, Jiang Y, Reitzel R, Raad I. Utility of galactomannan enzyme immunoassay and (1,3) beta-D-glucan in diagnosis of invasive fungal infections: low sensitivity for Aspergillus fumigatus infection in hematologic malignancy patients. J Clin Microbiol 47(1):129-33, 1/2009.
19. Torres HA, Aguilera E, Safdar A, Rohatgi N, Raad II, Sepulveda C, Luna M, Kontoyiannis DP, Chemaly RF. Fatal cytomegalovirus pneumonia in patients with haematological malignancies: an autopsy-based case-control study. Clin Microbiol Infect 14(12):1160-6, 12/2008. PMID: 19046167.
20. Ghanem G, Hachem RY, Chemaly RF, Dvorak T, Hulten K, Graviss L, Raad II. The role of molecular methods in the prevention of nosocomial methicillin-resistant Staphylococcus aureus clusters in cancer patients. Am J Infect Control 36(9):656-60, 11/2008. PMID: 18834742.
21. Raad I, Reitzel R, Jiang Y, Chemaly RF, Dvorak T, Hachem R. Anti-adherence Activity and Antimicrobial Durability of Anti-infective-Coated Catheters Against Multidrug-Resistant Bacteria. J Antimicrob Chemother 62(4):746-50, 10/2008. PMID: 18653489.
22. Winston DJ, Young JA, Pullarkat V, Papanicolaou GA, Vij R, Vance E, Alangaden GJ, Chemaly RF, Petersen F, Chao N, Klein J, Sprague K, Villano SA, Boeckh M. Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem-cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study. Blood 111(11):5403-10, 6/2008. PMID: 18285548.
23. Lamaris GA, Esmaeli B, Chamilos G, Desai A, Chemaly RF, Raad II, Safdar A, Lewis RE, Kontoyiannis DP. Fungal endophthalmitis in a tertiary care cancer center: a review of 23 cases. Eur J Clin Microbiol Infect Dis 27(5):343-7, 5/2008. PMID: 18183439.
24. Youssef S, Hachem R, Chemaly RF, Adachi J, Ying J, Rolston K, Raad I. The role of vitamin B6 in the prevention of haematological toxic effects of linezolid in patients with cancer. J Antimicrob Chemother 61(2):421-4, 2/2008. PMID: 18174198.
25. Chemaly RF, Torres HA, Hachem R, Kontoyiannis DP, Safdar A, Raad II. Human herpesvirus-6 DNAemia in immunosuppressed adult patients with leukemia at risk for mold infection. Haematologica 93(1):157-8, 1/2008. PMID: 18166808.

Grant & Contract Support

Title: Impact of pulsed xenon ultraviolet disinfection on the acquisition rate of VRE and the overall nosocomial infection rate in the Hematopoietic Stem Cell Transplant Unit
Funding Source: Xenex, Inc.
Role: Principal Investigator
Duration: 2/11/2012 - 2/28/2013
 
Title: A Randomized, Double-Blind, Placebo-Controlled Phase II Study Evaluating the Safety and Efficacy of Preemptive Treatment with CMX001 for the Prevention of Adenovirus Disease Following Hematopoietic Stem Cell Transplantation in Adults and Children (the ADV HALT Trial) (CMX001-202)
Funding Source: Chimerix, Inc.
Role: Principal Investigator
Duration: 5/9/2011 - 5/31/2013
 
Title: A Companion Protocol to the Clinical Study a Randomized, Placebo-controlled, Multi-site Phase II Study Evaluating the Safety and Efficacy of Preemptive Treatment with CMX001 for the Prevention of Adenovirus Disease Following Hematopoietic Stem Cell Transplantation (CMX001-202 Lab)
Funding Source: Chimerix, Inc.
Role: Principal Investigator
Duration: 5/9/2011 - 5/8/2013
 
Title: A Phase III International, Randomized, Double-blind, Double Dummy Study to Evaluate the Efficacy and Safety of 300 mg or 600 mg of Intravenous Zanamivir Twice Daily Compared to 75 mg of Oral Oseltamivir Twice Daily in the Treatment of Hospitalized Adults and Adolescents with Influenza
Funding Source: Glaxo Smith and Kline
Role: Principal Investigator
Duration: 4/28/2011 - 4/27/2013
 
Title: A Randomized Double-blind, Placebo-controlled Trial to Evaluate The Safety, Tolerability, and Antiviral Activity of 12-weeks Treatment With a New Antiviral Drug
Funding Source: Aicuris
Role: Principal Investigator
Duration: 5/27/2010 - 5/31/2013
 
Title: An Open-Label, Multi-Center, Single Arm Study to Evaluate the Safety and Tolerability of Intravenous Zanamivir in the Treatment of Hospitalized Adult, Adolescent and Pediatric Subjects with Confirmed Influenza Infection.(NAI113678)
Funding Source: Glaxo Smith and Kline
Role: Principal Investigator
Duration: 5/9/2010 - 6/30/2013
 
Title: A Randomized, Double -Blind, Placebo-Controlled Study To Assess The Efficacy And Safety of Prophylactic Use of Maribavir For The Prevention of Cytomegalovirus Disease in Recipients of Allogeneic Stem Cell Transplants
Funding Source: Viropharm Inc.
Role: Principal Investigator
Duration: 11/8/2008 - 10/8/2009
 
Title: Clinical Experience With Tigecycline
Funding Source: Wyeth Pharmaceuticals
Role: Principal Investigator
Duration: 1/1/2006 - 12/31/2008

Last updated: 3/27/2014